Growth Hormone Treatment and Papilledema: A Prospective Pilot Study

Nieves Martín-Begué Eduard Mogas Charlotte Wolley Dod Silvia Alarcón María Clemente León Ariadna Campos-Martorell Ana Fábregas Diego Yeste Fernández

Published in: Journal of clinical research in pediatric endocrinology (2020)

GH treatment is a cause of PTCS. In our series, at risk patients had GH deficiency and hypothalamic-pituitary anatomic anomalies or genetic or chromosomal diseases. Fundus examination should be systematically screened in all patients in this at-risk group, irrespective of the presence or not of symptoms.

Keyphrases

growth hormone
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
peritoneal dialysis
gene expression
patient reported outcomes
diabetic retinopathy
combination therapy